Patent ID: 8410168

Claim:
A method for treating macular degeneration in a mammal comprising administering to the mammal at least once an effective amount of a first compound having the following structure: wherein X 1 is selected from the group consisting of NR 2 , O, S, CHR 2 ; R1 is (CHR 2 )x-L 1 -R 3 , wherein x is 0, 1, 2, or 3; L 1 is a single bond or —C(O)—; R 2 is a moiety selected from the group consisting of H, (C 1 -C 4 )alkyl, F, (C 1 -C 4 )fluoroalkyl, (C 1 -C 4 )alkoxy, —C(O)OH, —C(O)—NH 2 , —(C 1 -C 4 )alkylamine, —C(O)—(C 1 -C 4 )alkyl, —C(O)—(C 1 -C 4 )fluoroalkyl, —C(O)—(C 1 -C 4 )alkylamine, and —C(O)—(C 1 -C 4 )alkoxy; and R 3 is H or a moiety selected from the group consisting of (C 2 -C 7 ) alkenyl, (C 2 -C 7 )alkynyl, aryl, (C 3 -C 7 )cycloalkyl, (C 5 -C 7 )cycloalkenyl, and a heterocycle, wherein the moiety is optionally substituted with 1-3 substituents independently selected from the group consisting of halogen, OH, O(C 1 -C 4 )alkyl, NH(C 1 -C 4 )alkyl, O(C 1 -C 4 )fluoroalkyl, and N[(C 1 -C 4 )alkyl] 2 ; or a pharmaceutically acceptable salt or solvate thereof; provided that R 3 is not H when both x is 0 and L 1 is a single bond.